Modality
ADC
MOA
TYK2i
Target
RET
Pathway
STING
NSCLC
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
Apr 2017
→ Dec 2027
Phase 1Current
NCT03468933
1,435 pts·NSCLC
2017-04→2027-12·Active
1,435 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-031.7y awayInterim· NSCLC
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Active
Catalysts
Interim
2027-12-03 · 1.7y away
NSCLC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03468933 | Phase 1 | NSCLC | Active | 1435 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET |